• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Scoop: Gilead out­lines plans to mus­cle up its man­u­fac­tur­ing arm af­ter Im­munomedics lay­offs

4 years ago
Pharma
Manufacturing

Big Phar­ma hits pause on tri­als in Rus­sia, Ukraine as they ramp up hu­man­i­tar­i­an aid

4 years ago
Pharma

Af­ter com­ing out of bank­rupt­cy, Mallinck­rodt pays out $260M to set­tle Ac­thar Gel law­suits

4 years ago
Pharma
Law

Phar­ma com­pa­nies in the meta­verse? Maybe not yet, but time to start think­ing fu­ture use, ex­perts say

4 years ago
Pharma
Marketing

The first liv­ing re­cip­i­ent of an an­i­mal or­gan in decades dies, just months af­ter surgery

4 years ago
Pharma

A trio of amy­loid-tar­get­ed Alzheimer's drugs will soon see key re­sults, but an an­a­lyst pre­dicts on­ly 50-50 odds for ...

4 years ago
R&D
Pharma

Sanofi sets up a ti­tle fight with Roche in he­mo­phil­ia A — pro­vid­ed gene ther­a­pies don't beat them to the punch

4 years ago
R&D

Gilead to lay off 110+ em­ploy­ees at for­mer Im­munomedics HQ in an­oth­er ding for its $21B deal

4 years ago
People

FDA's on­col­o­gy ad­comm to re­view PI3K in­hibitors in blood can­cers in April

4 years ago
R&D
FDA+

Nat­era shares tum­ble af­ter short-sell­er al­leges de­cep­tive billing prac­tices — and pos­si­bly in­sur­ance fraud

4 years ago
News Briefing

BeiGene hema­tol­ogy CMO Jane Huang makes a quick jump to a strug­gling biotech now jug­gling pipeline projects

4 years ago
People

Last-minute US spend­ing bill fea­tures a be­gin­ning for ARPA-H, and half of what Biden re­quest­ed for Covid-19

4 years ago
FDA+
Coronavirus

Black­stone leads $200M in­jec­tion in­to da­ta analy­sis soft­ware mak­er

4 years ago
Financing

For­mer Zymeworks CEO Ali Tehrani lands at Cana­di­an VC Am­pli­tude, look­ing to guide new com­pa­ny builders 'punch­ing ...

4 years ago
People

Mod­er­na’s new patent pol­i­cy is a mixed bless­ing for WHO ef­fort to repli­cate com­pa­ny's vac­cine

4 years ago
Coronavirus

Ab­b­Vie set­tles one of its fi­nal Hu­mi­ra biosim­i­lar suits for an­oth­er mid-2023 de­layed en­try

4 years ago
Pharma
Law

Lu­l­ule­mon founder com­mits $100M to cure his rare dis­ease

4 years ago
R&D
Discovery

Ex­clu­sive: ARCH and GV are build­ing a large start­up fo­cused on mi­to­chon­dr­i­al dis­eases

4 years ago
Startups

From J&J on­col­o­gy chief to tiny biotech start­up CEO? Serge Messer­lian talks about his big ca­reer change­up

4 years ago
People

Ho­log­ic inks glob­al women’s ten­nis spon­sor­ship in lat­est sports tie-in fol­low­ing its Su­per Bowl de­but

4 years ago
Pharma
Marketing

FDA res­ur­rects pro­pos­al to gauge qual­i­ty met­rics in phar­ma man­u­fac­tur­ing

4 years ago
FDA+
Manufacturing

Sanofi CEO Paul Hud­son sketch­es a $1B-plus in­vest­ment on its new mR­NA cen­ter

4 years ago
Pharma
Manufacturing

Am­gen gets the dirt fly­ing on its new $550M man­u­fac­tur­ing site as phar­ma build­ing booms in NC

4 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Lund­beck’s Vyep­ti joins mi­graine TV ad bat­tle; Pfiz­er de­buts Covid treat­ment TV ad

4 years ago
Pharma
Marketing
First page Previous page 561562563564565566567 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times